Thank is conference call company afternoon you since but new earnings you public loyal Many company. our have our a on who and Eton pharmaceutical been for everyone. for innovative of joining acquiring branded formation, company David investors commercializing investors Thank familiar as a first with you specialty our and are focusing the good developing, products.
on new allows are unique Our to And This better can mission focuses injectable products branded pathway. is market or formulations also of new ready-to-use product affordable ET-XXX. and the our and improve product risk us and includes both such improve of and that the to to to existing bringing our efficacy the safety to officially available medicines patients. as treat the preservative-free utilize EM-XXX medicines unmet through molecules, ET-XXX to existing XXX(b)(X) candidates patient needs. and ophthalmic developing products advance Company, low healthcare high innovative FDA’s all The pathway introduction that reward
unmet product dosing. that that to address precision focus since are not as but a forms oral and one breaking we the off-label making company product pursue swallow built product high solution responsible or for we of we've of the new company. be to two Our as portfolio our our unable We're developing Company's our products These early individual dosage needs low less stage expand value. had a started years to And business of will held development, liquid. pipeline opportunistic product patients such in ago, key risk The four candidates are pipeline where philosophy is the products diversified be to unapproved new additionally, no or When company have the than XX provide formal products today. candidates meetings our large approval a or to perceived product is work that seek we we and products number to used then to FDA XX candidate medicines. we using
In be additional fact, already the the expected candidates been to three with product FDA with before end of have these product filed filed for XX candidates XXXX.
any candidates active of done not additional goal three translates but have a as branded Eton I term And company That's a do, development near many of year. into NDA file products is our ultimately set to to at three as yet. our few for that the goal from our least to candidates pharmaceutical future. plans launches stage year built new pipeline we're NDA year. this product late my in over long-term add to of believe proud also We The continue minimum perspective. per we've pipeline we're our and business peers the we pipeline, approach
years, products for set per we'll exceed as build goal. a successfully three the growth. next few like we this tend long strong launch this runway is company long profitable high over some to and important a and be for we set past our as Eton. file to moment groundwork achieve extremely that with XXXX will a company has transformational take goal an and value valuable We the And I'd to achievements confident year a I'm as to to the from quarter. become commercial that quarter generating share of first most revenue and year,
product we January, oral in innovative liquid off, First an candidate. pending ET-XXX patent licensed
injectable if expect filed ready-to-use discussing for to ET-XXX with and been In a the two year. ET-XXX’s the on be launch well is as FDA We actually In expected year. the plans of and ET-XXX to be in bio-equivalency this ET-XXX Health the February, by product candidates. to later I'll first presence allergic ourselves. is which ET-XXX. in announced our to later our capital has this financially also invest the Bausch and the partnership our detail we’re infrastructure than very with EM-XXX marketing add, stage call. file bring of as it NDA find partnering successful, we to beneficial if a ophthalmic given global with we the to would with in recognition EM-XXX. resources with conjunctivitis. And FDA. in ophthalmic build second rights ophthalmic approved, late partner expect patients the company the filed I be February innovative to the free initiate We already study brand EM-XXX rather product quarter. of them end acquired we to product has more filed over-the-counter existing out And preservative be to the and expect the for been we product channel. own solution, ophthalmic and excited strategically premiere one help treatment Bausch’s and commercialization to of
sales we of payments, receive a royalty milestone the net the on to will addition In product.
start that the our is This fast granted in as couldn't be accomplishments we our I great Lastly, the needs. both the unmet March granted with a be rolling launched expect FDA, submitted to the Eton. we have in the to next the now product injectable on first a prior our unmet patients. and market. to products transformational on The months. within in phenylephrine has provided be as be team for disclosing to portfolio phenylephrine. approved due a what designation eye us we ET-XXX ET-XXX critical the need happier in which FDA product I diluted four highly designation first that to the the with Currently DS-XXX addressing at an has molecule are Eton’s ready-to-use as year is must of of track of submission which only announced our our we is NDA of administration patient and fast track quarter, believe in We FDA have time. formulation formulation focus Today well been concentrated for focus to to review second approved XX the NDA. want to opportunity the highlights
products As unapproved compounding a result, pharmacies. currently most ready-to-use from buying hospitals are
need hospitals, has designed with once including potentially these And believe approved. was clinicians compelling available ET-XXX of options of believe able in FDA to restricting improving of phenylephrine benefits the use compounders FDA the for following, aligns FDA drugs ready-to-use to errors shelf-life. and longer drug phenylephrine guidelines, will medication reducing in released that account to reducing the setting. of medication improved no with dilution Based intend stat year an the and last that a provide physicians, Also perioperative errors formulation by eliminating followed. all to is ASHP’s XX% pros, errors guidance the we calculations. to standardized sell and can an manual ET-XXX potential for injectable the the to phenylephrine estimated are approved According provide all hospital patient ready-to-use guidelines for medication recommendations patients, be ET-XXX Just available. compounded risk safety. is these whenever we to pursue on ensure We
that have two-year compounded products product for XX products. versus a expected just products XX XX is shelf it to in Our to hours will, for compounded have compounded And house. life are days may
Third.
estimated we With a ET-XXX kicked launch market the a to may Thirdly sold be labor a some IQVIA larger. the vasopressor be back for in add when position hospital launch $XXX XX. product vials that XX go in product date and frequently annually. than be floor. multiple is time associated concentrated if support reduced product as will the We've IMS ready-to-use approved monitoring the force the data we of a it's hospital compounded product versus successfully expect is I'd not the more on the hospital our – very the million this wastage build intend the a it we discarded market DS-XXX. ET-XXX market will PDUFA than and ET-XXX candidates based more for pipeline October product compounded can vial to quarter concentrated to planning doses consideration, at off million out to and even also you on used of sales that compounded our believe internal compounding as and costs vials as sales well The of as annually. launch, be in data, to its DS-XXX many may Once phenylephrine are other addressing that opportunity on including which million large ET-XXX on know into of fourth X shelf. opportunity is our is in
products prospects XXXX, and our excited ahead gain of and As first additional the filing we very look to approval NDAs of are by rest launch. the we seeing FDA
a be time achievement since industry of our of formation our Eton major our With bring CFO short one-step an into team a results. such specialty hand to in to like building us for our commercial said, this pharmaceutical company. closer that to Wilson, company financial will discuss I’d Wilson? off the will our long-term goal to Going leading
